The grades of 4 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Ocular Therapeutix Inc (OCUL) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of OCUL stock.

Innoviva, Inc.’s (INVA) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of INVA stock.

NovaBay Pharmaceuticals, Inc. (NBY) boosts its rating from a C to a B this week. NovaBay Pharmaceuticals, Inc. develops product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NBY stock.

This week, CymaBay Therapeutics, Inc. (CBAY) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of CBAY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.